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Kedar S. Lavingia, MD, Sadaf S. Ahanchi, MD, Richard E. Redlinger, MD, Navalkishor R. Udgiri, MBBS,
and Jean M. Panneton, MD, Norfolk, Va
Background: Intramural hematoma (IMH), penetrating atherosclerotic ulcer (PAU), and aortic dissection comprise a
spectrum of acute aortic pathologies. Although thoracic endovascular aortic repair (TEVAR) has increasingly been
applied to aortic dissection, there is a paucity of data on the anatomic effect of TEVAR for IMH. Our goal was to
investigate the extent of aortic remodeling after TEVAR.
Methods: A retrospective chart review from 2006 to 2012 was conducted on patients who underwent TEVAR for IMH.
Data were collected from the electronic medical record. Radiology images were reviewed and primary data points included
diameter (TLD) and volume measurements for aortic true lumen and total aortic diameter (TAD) and volume at the site
of maximal pathology. Aortic remodeling was evidenced by a TAD/TLD ratio closest to 1.0. Patients with no imaging
beyond 30 days postoperatively were excluded.
Results: During the 6-year period, 44 patients underwent TEVAR for IMH. Twenty-ﬁve patients had an IMH with
concomitant PAU. There were 25 (57%) female patients. Mean age was 71 6 11 years, and 40 (91%) patients had
hypertension. Operative indications included intractable pain in 31 (70%), rapidly progressing IMH or conversion to
dissection in 13 (30%), rupture in 10 (23%), and uncontrolled hypertension in 6 (14%). Technically successful TEVAR
was performed in all patients with 42 (95%) reporting complete relief of symptoms. The 30-day mortality rate was 5%
with a 5% rate of permanent paraplegia or paraparesis. At a mean follow-up of 26 months, there were no additional
aortic-related deaths and overall survival was 80% with a reintervention rate of 11%. For our imaging analysis, 10
patients were excluded because of lack of follow-up imaging beyond 30 days. At a mean follow-up of 13 months, all
measured data points were statistically improved from before to after TEVAR: thickness of IMH (12 mm vs 4 mm; P[
.01), mean TLD (35 mm vs 37 mm; P[ .04), mean TAD (47 mm vs 42 mm; P[ .02), TAD/TLD ratio (1.35 vs 1.14;
P < .01), and IMH volume (103 cm3 vs 14 cm3; P < .01). The mean D in TAD/TLD ratio from before to after TEVAR
for the reintervention group was D0.14, and the mean D in TAD/TLD ratio for the nonreintervention group was
D0.29 (P [ .05). Analysis of patients with isolated IMH and those with concomitant PAU revealed no statistical
differences.
Conclusions: TEVAR is safe and effective in treating IMH and based on longitudinal computed tomography scan analysis,
aortic remodeling is evidenced by normalization of all measured indices. (J Vasc Surg 2014;60:929-36.)Acute aortic syndrome (AAS) describes interrelated
aortic conditions with similar clinical characteristics and
symptomatology. These conditions represent a continuum
of penetrating atherosclerotic ulcer (PAU), intramural he-
matoma (IMH), and aortic dissection (AD). Population-
based studies suggest that the incidence of AAS ranges
from 2 to 3.5 cases per 100,000 person-years.1 Hyperten-
sion and a variety of genetic disorders with altered connec-
tive tissues are the most prevalent risk factors. The
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://dx.doi.org/10.1016/j.jvs.2014.04.015the aortic wall. If the hematoma is conﬁned to the media,
it is classiﬁed as an IMH. IMH is often described in the liter-
ature as an atypical AD because it is thought to represent
either early-stage limited dissection or thrombosis of the
false lumen in dissection. IMH is thought to have a preva-
lence of 5% to 20% in patients who present with signs sug-
gestive of AD and is associated with a mortality rate of
20% to 30%.2-4 To determine the anatomic effect of thoracic
endovascular aortic repair (TEVAR) on AD, Rodriguez et al
initially measured indices of true lumen and false lumen
diameters at multiple areas along the thoracic aorta and
demonstrated that TEVAR for acute AD promoted aortic
remodeling when the entry tear was covered.5 Manning
et al published a study of seven IMHpatients demonstrating
complete aortic anatomic normalization after TEVAR at a
mean follow-up of 44 months.6 This study comprised the
minimal body of research investigating the extent of aortic
remodeling after TEVAR for IMH.
Our aim was to study the effect of TEVAR for IMH on
aortic remodeling.
METHODS
Patient identiﬁcation. A retrospective review of the
electronic medical record (EMR) was conducted to929
Table I. Patient demographic characteristics and risk
factors
Variable Value (N ¼ 44 IMH)
Characteristic
Age, years 71 6 11
Female sex 25 (57)
Race
African American 8 (18)
Caucasian 24 (55)
Asian 6 (13)
Hispanic 2 (5)
Not identiﬁed 4 (9)
Body mass index 29 6 6
Risk factor
Smoker 32 (73)
Diabetes 3 (7)
Hypertension 40 (91)
Hyperlipidemia 33 (75)
Coronary artery disease 15 (34)
COPD 7 (16)
End-stage renal disease 3 (7)
COPD, Chronic obstructive pulmonary disease; IMH, intramural
hematoma.
Continuous data are presented as mean 6 standard deviation and categoric
data as number (%).
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Current Procedural Terminology coding from January
2006 through August 2012. All patient records who un-
derwent TEVAR in a consecutive series were reviewed
and patients with radiographic imaging consistent with
IMH were analyzed. Images were also reviewed for
concomitant aortic pathology including dissection, PAU,
and aneurysmal changes. IMH currently does not have a
proper International Classiﬁcation of Diseases, Ninth Revi-
sion code so we were unable to query patients based on this
diagnosis. Our protocol included admission to a vascular
intensive care unit, strict blood pressure control, and
aggressive analgesia with subsequent repair if there was
no improvement in symptomatology. Patients with rapid
IMH expansion or concern for rupture were treated with
immediate surgical therapy. The EMR review was per-
formed with approval of the Eastern Virginia Medical
School’s Institutional Review Board with patient consent
waived for minimal risk study and in compliance with the
Health Insurance Portability and Accountability Act.
Outcome measures and data analysis. Patient demo-
graphic characteristics, morphologic nature of the aortic
lesion, procedural information, outcome, complication,
and follow-up data were collected from the EMR.
Continuous data were expressed using mean 6 standard
deviation on all clinical and morphological variables with c2
test used for categorical variables and Student t-test used
for continuous variables. A value of P < .05 was considered
to be statistically signiﬁcant.
Radiologic measurements. All preoperative and post-
operative computed tomography (CT) images taken >30
days postoperation were analyzed using a TeraRecon digital
workstation (TeraRecon iNtuition Workstation; TeraRe-
con, Foster City, Calif). Primary data points included diam-
eter measurements of transverse cross sectional CT scans;
aortic true lumen diameter (TLD) and total aortic diameter
(TAD) at the site of maximal aortic pathology. All CT scan
coronal and axial slices with evidence of IMH were
analyzed. The TLD was measured from intima to intima
and TAD was measured from adventitia to adventitia and
thus included the normal aortic wall thickness. The
maximal values of TLD and TAD within the area of the
IMH were then recorded. IMH thickness was calculated
by subtracting TLD from TAD. Aortic pathology was
quantiﬁed as a TAD/TLD ratio greater than 1.0 and aortic
remodeling was evidenced by a TAD/TLD ratio approach-
ing 1.0. Postoperatively, the TAD and TLD were measured
at similar locations on follow-up scans based on anatomic
landmarks. Preoperative CT scan data points were then
compared with postoperative CT scan data points. For
volumetric measurements, the volumes of interest were
outlined on each CT slice manually with the cursor of the
workstation using center line isolation of the diseased
segment of the aorta. Volume measurements of the true
lumen volume and total aortic volume were obtained using
the summation of area technique of the TeraRecon soft-
ware. The volume of the IMH was calculated by sub-
tracting true lumen volume from total aortic volume.RESULTS
Patient demographic characteristics and presenta-
tion. During the 6-year interval, 44 patients with IMH
underwent TEVAR. Nineteen (43%) had isolated IMH
and 25 (57%) had IMH with identiﬁable PAU. Concom-
itant thoracoabdominal aortic aneurysm (TAAA) was pre-
sent in 5 (11%) patients and descending thoracic aneurysm
(DTA) was present in 4 (9%) patients. The mean age of
patients was 71 6 11 years and 25 (57%) were female. The
remainder of patient demographic and comorbidity data
are presented in Table I. Our ratio of male:female patients
(19:25) is a consequence of our patient population which is
traditionally older than 70 years of age, with 18% African
American, and a high proportion of patients with unman-
aged hypertension. For our area, this sex ratio in treating
aortic pathology is not unusual. Most patients presented
with either chest pain (70%) or back pain (61%). Our co-
hort’s presenting symptoms and operative indications are
shown in Table II. Ten (23%) patients had rupture with
hypotension. Of the two patients with malperfusion, one
had renal malperfusion with renal infarction and the other
presented with transient paraparesis secondary to spinal
cord ischemia. In our study population, the average time to
surgery from admission was 2 6 2 days. There were 13
(30%) patients who had at least two CT scans before sur-
gery. Of the 13, ﬁve patients showed progression of IMH
to dissection and one patient had retrograde IMH exten-
sion into the aortic arch. Over an average interval of 2 days,
the mean increase in IMH thickness was 11.2 mm 6
6.1 mm for this subset of patients.
Surgical data. Technically successful TEVAR was per-
formed in all patients with no intraoperative mortalities,
Table II. Presenting symptoms and operative indications
Variable Value (N ¼ 44 IMH)
Presenting symptom
Chest Pain 31 (70)
Back Pain 27 (61)
Abdominal Pain 15 (34)
Dyspnea 7 (16)
Paraparesis 1 (2)
Malperfusion 2 (5)
Operative indication
Intractable pain 31 (70)
Uncontrolled HTN 6 (14)
Rupture with hypotension 10 (23)
Rapid expansion
or progression to dissection
13 (30)
HTN, Hypertension; IMH, intramural hematoma.
Data are presented as number (%).
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tients with IMH and an identiﬁable PAU, the endografts
were deployed to cover the PAU and the length of the
IMH. In patients with rupture, the endografts were
extended distally to within 2 cm to 3 cm of the celiac trunk.
Thoracic endografts were deployed using a Talent or Valiant
in 29 patients (Medtronic Inc, Santa Rosa, Calif), a TX2 in
two patients (Cook Inc, Bloomington, Ind), or a TAG in
eight patients (W. L. Gore & Associates, Flagstaff, Ariz).
Five patients received a combination of the different brands
of endografts available. The average number of stent grafts
used was two (range, 1-4). Thirty patients had multiple
endografts placed. Two patients had zone 1, 13 underwent
zone 2, 23 had zone 3, and 6 had zone 4 TEVAR deploy-
ments. Twenty-two adjunctive procedures were performed
in 21 patients: seven arch debranching, six left subclavian
artery (LSCA) laser fenestration, two visceral debranching,
ﬁve iliac conduits, and two endograft conduits. The two
patients with zone 1 deployment of the endograft under-
went arch debranching with right carotid artery to LSCA
bypass and left common carotid transposition. In the 13
patients with zone 2 deployment, ﬁve underwent left com-
mon carotid to LSCA bypass, six patients had laser fenes-
tration of the LSCA with iCAST stent (Atrium Medical
Corp, Hudson, NH) placement, and the remaining two
patients had coverage of the LSCA without revasculariza-
tion. Two patients with symptomatic TAAA and evidence of
IMH in the proximal thoracic aorta underwent total visceral
debranching. One had right ilio-right renal artery bypass;
right ilio-left renal artery bypass; right ilio-superior mesen-
teric artery bypass; and right ilio-celiac artery bypass. The
other patient received bilateral ilio-renal bypasses and ilio-
superior mesenteric artery bypass. All patients had femoral
access for graft delivery. Seven required an additional
conduit: ﬁve an iliac conduit, two endograft conduit, and
nine patients also had concomitant brachial access either
for LSCA revascularization or to facilitate diagnostic
imaging. Average operative time was 158 6 88 minutes.
Mean contrast volume administered intraoperatively was
1096 47 mL. The mean total length of aortic coverage was248 6 131 mm. Sixteen patients had lumbar drains placed
for cerebrospinal ﬂuid (CSF) drainage. Our indications for
CSF drainage included previous abdominal aortic aneurysm
repair, increased length of thoracic aortic coverage, subcla-
vian artery coverage, or coverage of the distal half of the
thoracic aorta.
Early outcome. Forty-two (95%) patients reported im-
mediate and complete resolution of presenting symptom-
atology and the remaining two patients reported
improvement in symptoms. There were two (5%) mortalities
within 30 days. One patient had a ruptured IMH and had
undergone previous open abdominal aortic aneurysm repair
and aortic arch reconstruction and her postoperative course
was complicated by paraparesis and respiratory failure lead-
ing to withdrawal of care and comfort measures. The second
mortality was in a patient with symptomatic DTA and IMH
of the proximal thoracic aorta and arch who required subto-
tal arch debranching, and the postoperative course was
complicated by paraplegia, acute renal failure, and respira-
tory failure again leading to withdrawal of care and comfort
measures. One patient had a minor stroke and had no resid-
ual deﬁcits at the 2-month follow-up. There was no inci-
dence of retrograde AD induced by TEVAR.
When comparing 35 patients without concomitant
aneurysm with the nine patients with, there was one death
in each group (3% vs 11%; P ¼ .3). The combined inci-
dence of neurologic complication was 6% vs 11% (P ¼
.52). There was one case of paraparesis in the nonaneurys-
mal group and one case of paraplegia in the aneurysmal
group. The patient with paraparesis had a CSF drain placed
preoperatively which was removed on postoperative day 4
and the patient with paraplegia did not have a CSF drain
placed. This patient also underwent a subtotal arch
debranching procedure with zone 1 TEVAR deployment.
The single minor stroke occurred in a patient with no aneu-
rysmal degeneration. The average hospital length of stay
was 9 6 8 (range, 2-33) days.
Late outcome. There were ﬁve aortic-related reinter-
ventions (11%); two for type I endoleak, one for type I and
type II endoleaks, one for partial graft collapse, and one for
isolated type II endoleak. Only one patient required rein-
tervention within 30 days of the initial surgery and that was
secondary to isolated type II endoleak from the LSCA. Of
the remaining four reinterventions, all patients underwent
repeat TEVAR and one patient had concomitant LSCA
coil embolization. One patient underwent repeat TEVAR
for graft collapse after 42 months from the index proce-
dure. The other patients required reinterventions between
11 and 14 months from the index procedure. All patients
who required reinterventions for endoleaks had either a
DTA or TAAA associated with IMH on presentation. No
aneurysmal degeneration at any time was present in the
patient who had graft collapse. At a mean follow-up of
26 months, there were no additional aortic-related deaths
and overall survival was 80%.
Radiographic ﬁndings. For our imaging analysis, 34
patients out of the 44 were reviewed after 10 patients
were excluded because of lack of imaging beyond 1 month
Fig 1. a, Close-up imaging demonstrating an aortic intramural hematoma (IMH). b, Postoperative ﬁndings
11 months after thoracic endovascular aortic repair (TEVAR) with near resolution of IMH.
Table III. Pre- and postoperative aortic diameters and
volume measurements
Preoperative Postoperative P
TAD, mm 47 6 12 42 6 10 .03
TLD, mm 35 6 9 37 6 9 .04
IMH thickness, mm 12 6 3 4 6 2 .01
TAD/TLD ratio 1.35 6 0.14 1.13 6 0.14 <.01
Volume of IMH, cm3 103 6 62 18 6 17 <.01
IMH, Intramural hematoma; TAD, total aortic diameter; TLD, true lumen
diameter.
Data are presented as mean 6 standard deviation.
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aging database. Preoperatively, average thickness of the
IMH was 12 6 4 mm, the mean TLD diameter was
35 6 9 mm, and the mean TAD was 47 6 12 mm
(Fig 1). The calculation for the TAD/TLD ratio before
intervention yielded a mean of 1.35 6 0.14. The average
volume of the IMH before the intervention was 103 6
62 cm3 (Table III; Fig 2).
At a mean radiological follow-up of 13 (range, 1-49)
months, the average thickness of the IMH decreased to
4 mm (P ¼ .01, vs preoperative of 12 mm). The mean
TLD increased to 37 6 9 mm (P ¼ .04, vs preoperative
35 mm). The mean TAD decreased to 42 6 10 mm
(P ¼ .02 vs preoperative 47 mm). The TAD/TLD ratio
normalized postoperatively to 1.13 6 0.14 from 1.35 6
0.14 preoperatively (P < .01). The mean increase in the
size of the TLD was D2 6 0.68 mm. The overall decrease
in the TAD was D6 6 0.69 mm (Table III). The average
volume of the IMH after intervention was 14 6 18 cm3
(P < .01). Twenty-ﬁve (74%) of the patients showed com-
plete normalization of the aorta with a TAD/TLD ratio of
1 at an average time of 11 (range, 2-18) months.
As discussed, there were ﬁve patients who underwent
reintervention either for endoleaks or graft collapse. The
ﬁve reintervention patients sustained less aortic remodeling
after TEVAR. The mean change in the TAD/TLD ratio
from before (1.42) to after surgery (1.28) in the CT scan
for the reintervention group was D0.14, which was statisti-
cally less than the mean change in the TAD/TLD ratio
from before to after surgery in the nonreintervention
group, which was D0.29 (P ¼ .05).
When comparing 14 patients with isolated IMH with
the 20 patients with concomitant PAU, there was no statis-
tical difference in the amount of aortic remodeling between
the two groups. In the IMH with PAU cohort, the preop-
erative TAD, TLD, and TAD/TLD ratio was 46 6
11 mm, 36 6 11 mm, and 1.30 6 0.1 mm, respectively,and postoperative data showed measurements of 40 6
11 mm, 37 6 7 mm, and 1.1 6 0.1 mm. In the IMH-
only cohort, the preoperative TAD, TLD, and TAD/
TLD ratio was 48 6 10 mm, 35 6 8 mm, and 1.37 6
0.1 mm, respectively, and postoperative data showed mea-
surements of 41 6 9 mm, 36 6 7 mm, and 1.1 6 0.2,
respectively. The mean DTAD/TLD ratio from before to
after surgery was 0.22 for the isolated IMH group and
0.23 for the IMH with PAU group (P ¼ .65).
Finally, we conducted an analysis using 28 patients who
did not have aneurysmal changes of the aorta vs the 6 who
presented with concomitant TAAA or DTA. The diameter
measurements were all statistically different when compared
with the nonaneurysmal group. In the aneurysm cohort, the
preoperative TAD and TLD was 62 6 7 mm and 47 6
8 mm, respectively, and postoperative data showed measure-
ments of 56 6 13 mm and 48 6 11 mm, respectively. The
IMH group without associated aneurysm had TAD and
TLD values of 44 6 11 mm (P ¼ .01, vs the aneurysm
group) and 33 6 7 mm (P < .01, vs the aneurysm group),
respectively, and postoperative data showed measurements
of 39 6 10 mm (P ¼ .02, vs the aneurysm group) and
35 6 6 mm (P ¼ .01, vs the aneurysm group), respectively.
Fig 2. Preoperative volumetric measurement using a TeraRecon
digital workstation (TeraRecon iNtuition Workstation; TeraR-
econ, Foster City, Calif).
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before (1.34 vs 1.34; P ¼ .77) to after surgery between
the groups (1.17 vs 1.12; P ¼ .48).DISCUSSION
PAU, IMH, and AD are typically described in the con-
tinuum of AAS, with IMH being a hematoma usually
conﬁned to the media and PAU being a focal intimal defect
with a small area of ﬂow outside the ﬂow lumen within the
parameters of the intimal defect. IMH occurs secondarily
to a rupture of the vasa vasorum or hemorrhage within
an atherosclerotic plaque followed by aortic wall infarction,
which, in turn, weakens the actual wall, possibly resulting
in frank AD with potential rupture. Conservative manage-
ment with analgesia and aggressive blood pressure control
is the mainstay of therapy, and is advocated in patients with
descending thoracic IMH (type B), similar to recommen-
dations for uncomplicated acute type B ADs. Our manage-
ment protocol included admission to an intensive care unit
with aggressive blood pressure control using intravenous b-
blockade and aggressive analgesia for pain control. We
reserved intervention for recurring or refractory pain,
rapidly increasing extent or thickness of the IMH, or for
progression to AD. Anatomic factors previously described
in the literature that would prompt surgical intervention
include aortic diameter >4.0 cm and IMH thickness
>10 mm. Patients who presented with rupture were
treated with emergent surgical intervention. This approach
is based on the observation that mortality rates of <10%
can be achieved with optimal medical therapy in stable pa-
tients with uncomplicated type B IMH or AD, and that
surgical intervention should be reserved for patients who
present with complications.7-10
A major concern of performing TEVAR for IMH is the
potential risk of TEVAR-induced transformation of the
IMH into a dissection. This iatrogenic complication could
be caused by the leading edge of the stent graft penetrating
through the aortic wall either at the proximal or distal land-
ing zones. To avoid this complication, the area of maximal
IMH thickness should be completely excluded and at a safe
distance from the leading edge of the endograft. Similar to
our experience with TEVAR for AD, we abstain from using
an aortic balloon for graft apposition and we limit the graft
oversizing to 10% of the aortic diameter. In our experience,
we had no such TEVAR-induced conversion, but we did
have to extend the TEVAR into zone 1 and 2 in 15 of
our patients to place the proximal edge of the endograft
cephalad of the area of maximal IMH thickness.
The acceptable long-term mortality rates of patients
with uncomplicated stable IMH managed using optimal
medical therapy occurs because a large proportion of pa-
tients, between 50% and 80%, will undergo almost com-
plete aortic normalization within 3 to 10 months.11-17
However, some IMH patients can also progress to frank
dissection, rupture, or late aneurysm formation and it re-
mains difﬁcult to predict who will exhibit this worse
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with a higher likelihood of progression or rupture: elderly
patients, aortic diameter >4.0 cm, and IMH thickness
>10 mm.18-22 Our IMH population exhibited a high prev-
alence of these risk factors for progression with a mean age
of 70 years, a mean aortic diameter of 4.6 cm, and a mean
IMH thickness of 12 mm. Twenty-four patients had an
IMH thickness $10 mm and 10 patients had an IMH
thicker than 15 mm. As expected because of their high-
risk characteristics, 10 patients presented or progressed to
rupture, ﬁve patients progressed to frank dissection, and
one patient progressed to retrograde IMH extension into
the arch.
In addition to these high-risk variables, most of our
population had concomitant PAU, which has been identi-
ﬁed as another independent high-risk variable for IMH
progression or rupture. Ganaha et al showed that 48% of
patients with PAU progressed to dissection vs only 8% in
the isolated IMH group.4 When we identiﬁed a concomi-
tant PAU, that pathologic segment of aorta was covered
by the endograft, in the same manner as the endograft
should cover the primary entry tear of an AD. In absence
of an identiﬁable PAU or point of entry for the IMH, we
ensured that the area of greatest thickness was included
in the covered segment. The extent of proximal and distal
coverage required beyond that pathologic segment is not
clearly deﬁned and was left at the discretion of the oper-
ating surgeon. In general, similar to the situation with
AD when a distal extension is required to optimize true
lumen expansion, the extent of distal coverage is a balance
between bringing the distal edge as far away from the
thicker portion of the IMH vs compromising spinal cord
perfusion. In patients with rupture, the TEVAR was
extended distally to within a few centimeters of the celiac
trunk. In our experience, endovascular treatment of IMH
with or without PAU resulted in similar procedural out-
comes and normalization of aortic anatomy.
As far as quantifying aortic remodeling after TEVAR for
IMH, our methodology has been extrapolated from reports
on the outcomes of patients undergoing TEVAR for AD.
Multiple studies in the setting of acute and chronic type B
AD have shown that TEVAR promotes aortic remodeling,
indicated by a decrease in false lumen diameter and TAD
within as early as 6 to 12 months postoperatively.5,23,24
Manning et al reported on a small subset of IMH patients
with almost complete resolution of the IMH after TEVAR
using postoperative CT imaging at a mean follow-up of
44 months.6 Our data also conﬁrmed that IMH thickness
and aortic diameter were reduced by TEVAR, suggesting
positive aortic remodeling. Few studies have been conduct-
ed on the utility of volumetric analysis because volumetric
measurements are time-consuming and therefore less likely
to be used clinically. Our volumetric analysis demonstrated
a signiﬁcant decrease in the IMH volume after TEVAR
from 103 cm3 to 14 cm3, suggesting resolution of the
IMH and restoration to normal aortic volumetrics. These
ﬁndings are consistent with the reported data on volumetrics
after TEVAR for AD.25Our data not only showed these improvements in
aortic diameters and volumes, but also best illustrated
this aortic remodeling by the normalization of the TAD/
TLD ratio to 1 after TEVAR. Furthermore, our experience
revealed that the ﬁve patients who required aortic-related
reinterventions had a statistically smaller improvement in
TAD/TLD ratio after TEVAR, suggesting a blunted aortic
remodeling response in patients with concomitant aneu-
rysms. Nine patients had an IMH with a concomitant
thoracic aortic aneurysm, this is compared with 35 patients
with IMH without any aneurysmal changes in the aorta.
Aneurysm was deﬁned as maximal TAD >6 cm. Our
data collection afforded us the opportunity to evaluate
the change in overall aortic anatomy after TEVAR, but
was not powered to compare isolated IMH with IMH
and aneurysm. In this limited experience, both groups
demonstrated normalization of aortic parameters and
similar procedural outcomes.
We also included nine complex reconstructions in our
IMH database (20%). Two were in the form of right ca-
rotid artery to LSCA bypass and left common carotid trans-
position, ﬁve patients underwent left common carotid to
LSCA bypass, and two underwent total visceral debranch-
ing. Although these cases might not represent the natural
history of isolated IMH, they illustrate the concept that
endovascular repair of aortic pathology (in this case isolated
IMH or IMH with DTA or TAAA) promotes aortic wall
normalization.
Understandably, our study has major limitations. First,
this is a retrospective study in which the data were gathered
from review of the EMRs and as such, some data points
were incomplete. Additionally, our follow-up time was var-
iable and ranged from 1 to 49 months, with a small fraction
of patients being excluded from imaging analysis for lack of
late CT scan follow-up. Last, we did not have a control
group to compare the extent of aortic remodeling after
TEVAR with patients treated with optimal medical man-
agement. Because IMH does not have a proper Interna-
tional Classiﬁcation of Diseases, Ninth Revision code
further compounds this problem and complicates the iden-
tiﬁcation of patients with IMH treated conservatively.
Further study is needed to clarify the clinical and anatom-
ical natural course of IMHs treated with optimal medical
management, but this longitudinal CT scan analysis of
aortic diameters and volumes provided useful measure-
ments to quantify aortic remodeling in the setting of
TEVAR for IMH.
CONCLUSIONS
TEVAR for IMH can be performed safely and was
effective at relieving presenting symptoms in most patients.
Longitudinal CT scan analysis demonstrated signiﬁcant
normalization in all aortic measurements, conﬁrming that
TEVAR promotes positive aortic remodeling in most pa-
tients. Longer follow-up, larger patient population, and
comparison with a cohort of patients managed nonsurgi-
cally are necessary to determine the best treatment strategy
for patients with IMH of the descending thoracic aorta.
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Submitted Jan 28, 2014; accepted Apr 6, 2014.DISCUSSIONDr Jeffery B. Dattilo (Nashville, Tenn). Dr Bercelli, Dr
Endean, members of the program committee; I wish to express
my gratitude for being asked to review this manuscript from our
colleagues from Eastern Virginia. The manuscript is well written
and I appreciate the communication regarding the report before
the meeting, giving me ample time for review.
Clearly this is a controversial topic, as the remaining member-
ship present on this beautiful Saturday, will undoubtedly agree.
Historically, as the authors admit, nonsurgical aggressive medical
management was and still remains the mainstay of treatment for
these descending aortic conditions. The modern literature, howev-
er, suggests that endoluminal repair of these pathologies is gaining
momentum primarily because of the initial technical success rate
and fewer comorbid consequences of open surgical therapy. Thisoften requires more coverage of the descending aorta because
the nidus of the injury cannot always be readily identiﬁed and
thus subjecting the patient to dreaded complications such as
paraplegiadwhich was not inconsequentialdin your cohort of
patients.
I have a couple of questions.
Your group had, on average, seven patients per year that you
treated with endoluminal therapy. Do you have the numbers of the
patients you treated with traditional medical management of pain
control and aggressive blood pressure control? I ask because the
number of treated patients seems somewhat high for a single
institution.
You intimated that there would be follow-up computed to-
mography (CT) scans performed during the initial hospitalization.
JOURNAL OF VASCULAR SURGERY
936 Lavingia et al October 2014Do you have protocols for the timing of these scans to see progres-
sion? What if you don’t treat endoluminallydwhen do you see
these patients back in clinic?
Because intractable pain was one of your primary end points
compelling you to intervene and this can be enormously
subjectiveddo you have standardized pain control protocols? Do
you involve pain management teams at your institution?
I look forward to your answers and ﬁnally, Dr Lavingia, I wish
you every bit of good fortune in your quest for publication of this
manuscript. I appreciate the opportunity to discuss this issue
among the membership.
Dr Kedar S. Lavingia. First of all, I would like to thank you
for your kind comments and questions. Addressing your ﬁrst ques-
tion about patients treated with medical therapy, we are currently
working on identifying patients who did not receive endovascular
intervention and, unfortunately, cannot provide that information
right now. The difﬁculty in establishing that cohort is that there
is no speciﬁc International Classiﬁcation of Diseases-Ninth Revi-
sion code for intramural hematoma and these patients need to
be separated from a larger cohort of patients with an International
Classiﬁcation of Diseases-Ninth Revision code of thoracic or thor-
acoabdominal aortic dissection. At our institution, we seeapproximately two acute aortic syndrome cases a week, so there
is a signiﬁcant group of patients being treated with medical
management.
In regard to your second question on follow-up imaging, we
do have protocols in place. All patients who are admitted for
intramural hematoma undergo CT imaging on admission and
before discharge with follow-up in our ofﬁce in 1 to 3 months
after discharge. They also receive imaging at six months and at
one year and yearly thereafter. When we observe aortic remod-
eling, the imaging interval is increased to 2 to 3 years. All pa-
tients treated with TEVAR underwent a similar CT imaging
protocol.
As far as your third question regarding pain control, all pa-
tients were initially managed with intravenous morphine or dilau-
did and subsequently transitioned to patient-controlled analgesia if
they were going to be in the hospital for extended periods of time.
We typically do not involve our pain management teams but have
most success managing these patients’ pain with aggressive blood
pressure control. In our series, most patients had objective indica-
tions to intervene such as rupture or progression to dissection
whereas intractable pain alone was an uncommon surgical
indication.
